Bristol-Myers Squibb Company (BMY)
NYSE • Healthcare
August 18, 2026 at 20:00 UTC
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) develops, manufactures, and sells prescription medicines as a large biopharmaceutical company in healthcare. Across hematology, cancer, cardiovascular, immune, neurological, fibrotic, and infectious-disease treatment areas, it generated $48.2 billion of revenue in FY2025 through a portfolio that spans oncology, immunology, and cardiovascular therapies.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Bristol-Myers Squibb Company's Technical Indicators Summary
BMY displays a robust bullish profile with the price near $66.05 trading above short-, medium-, and long-term averages, including the 200-day, and a strong ADX around 43 confirming trend strength. Momentum readings are positive and CCI shows notable upside pressure, while MACD is supportive and volatility is moderate with an ATR near 2.5%. Volume trends are favorable—OBV is substantial—and the classic pivot lies below the market, reinforcing support. Technical takeaway: indicators favor a strong buy stance.
| Indicator | Value |
|---|---|
RSI (14) | 64.45 |
Stochastic %K (14, 3, 3) | 44.41 |
CCI (20) | 135.19 |
WPR (14) | -34.92 |
Momentum (10) | 0.16 |
MFI | 60.78 |
MACD Level (12, 26) | 1.38 |
Bollinger Bands | $61.11 - $66.78 |
ATR (14) | $1.65 (2.50%) |
ADX (14) | 42.96 |
OBV | 94,137,677 |
Classic Pivot Point | $64.24 |
Fibonacci Pivot Point | $64.24 |
Simple Moving Averages | $56.82 - $64.38(5 indicators) |
Exponential Moving Averages | $56.04 - $64.50(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
BMY logged a healthy uptick in the previous session, rising 2.20% from 64.63. Great Lakes Advisors LLC makes a new investment in BMY.
Trading Volume
Below 10d avg (9.2M)
6.6M
vs S&P 500 Today
Outperforming Market
+2.89%
52-Week Position
Near highs
92%
Updated: August 19, 2026 at 12:02 UTC
Quote Summary
BMY Headlines
AstraZeneca, BMS weigh mega-merger
August 3, 2026
Wall St futures rise on Mideast deal hopes
August 3, 2026
AstraZeneca, BMS discuss $400bn tie-up
August 2, 2026
Fresh Valuation Checks Across Key Stocks
April 4, 2026